You will find this Annual Report on our website, astrazeneca.com/ annualreport2012 Strategy To compete as a global biopharmaceutical business delivering great medicines to patients through innovative science and excellence in development and commercialisation Performance 2012 financial performance was defined by significant revenue decline associated with the loss of exclusivity for several products Corporate Governance In addition to the regular programme of meetings for the Board and its Committees 2012 was a busy year with new appointments, a record number of business development deals and our strategic review Financial Statements Met or exceeded financial targets as a result of disciplined financial management and lower Reported tax rate Additional Information More information about our business and about being an AstraZeneca shareholder Innovation is at the core of everything we do at AstraZeneca â€“ from our research into effective new medicines to how we run our business.